Frontiers in Medicine · 2020 · 175 citations · 14 references
Veterinary MedicineImmunologyInfectious DiseasesImmunology Of Infectious DiseasesImmunopathologyInflammationBacterial InfectionsInfectious InflammationInflammation In Infectious DiseaseAcute Inflammatory ResponseAutopsy InterpretationBiologic Anti-inflammatory TherapiesClinical AutopsyFungal Infections In Intensive Care UnitsInfection-related MortalitySecondary Infection PreventionSerious Bacterial Infection
Background: Anti-inflammatory therapies such as IL-6 inhibition have been proposed for COVID-19 in a vacuum of evidence-based treatment. However, abrogating the inflammatory response in infectious diseases may impair a desired host response and predispose to secondary infections. Methods: We retrospectively reviewed the medical record of critically ill COVID-19 patients during an 8-week span and compared the prevalence of secondary infection and outcomes in patients who did and did not receive tocilizumab. Additionally, we included representative histopathologic post-mortem findings from several COVID-19 cases that underwent autopsy at our institution. Results: 111 patients were identified, of which 54 had received tocilizumab while 57 had not. Receiving tocilizumab was associated with a higher risk of secondary bacterial (48.1% vs. 28.1%, p=0.029 and fungal (5.6% vs. 0%, p=0.112) infections. Consistent with higher number of infections, patients who received tocilizumab had higher mortality (35.2% vs. 19.3%, p=0.020). Seven cases underwent autopsy. In 3 cases who received tocilizumab, there was evidence of pneumonia on pathology. Of the 4 cases that had not been given tocilizumab, 2 showed evidence of aspiration pneumonia and 2 exhibited diffuse alveolar damage. Conclusions: Experimental therapies are currently being applied to COVID-19 outside of clinical trials. Anti-inflammatory therapies such as anti-IL-6 therapy have the potential to impair viral clearance, predispose to secondary infection, and cause harm. We seek to raise physician awareness of these issues and highlight the need to better understand the immune response in COVID-19.
14
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta, Daniel F. McAuley, Michael Brown et al. · The Lancet · 2020 · 10.2K citations · Full text
Effective treatment of severe COVID-19 patients with tocilizumab
Xiaoling Xu, Mingfeng Han, Tiantian Li et al. · Proceedings of the National Academy of Sciences · 2020 · 2.8K citations · Full text
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Manfred Köpf, Heinz Baumann, Giulia Freer et al. · Nature · 1994 · 1.8K citations
Life Sciences, Immunology, Pathology +16
Tocilizumab treatment in COVID‐19: A single center experience
Pan Luo, Yi Liu, Lin Qiu et al. · Journal of Medical Virology · 2020 · 1.3K citations · Full text